AstraZeneca

Lord Storey Excerpts

Thursday 6th February 2025 Lords Chamber

[Lord Vallance of Balham (Lab)]

I thank the noble Lord for his question. Yes, I am very aware of the need for funding in this area and for attracting external inward investment. The noble Lord may well know that a number of companies have been attracted to the UK recently, such as Eli Lilly, with a big deal of £279 million. Last week, Moderna opened its new facility in Harwell within two years. There is a lot going on in terms of inward investment, and the noble Lord is quite right to point out the importance of both NIHR and MRC funding as part of that process.

[Lord Storey (LD)]

My Lords, when the former Chancellor announced that AstraZeneca was set to inject £450 million into the establishment of a new manufacturing plant in Liverpool, the metro mayor hailed the investment as a vote of confidence in the work of the Liverpool combined authority, providing the new investment and jobs for local people that the plant would bring. Just days after the Chancellor laid out billion-pound plans mainly for the south-east, the so-called “golden triangle”, AstraZeneca, as we know, pulled out of Liverpool. Can the Minister tell us whether the metro mayor was involved in the discussions over AstraZeneca, and if not, why not? Secondly, how do the Government plan to develop the city’s life sciences and pharmaceutical sector?

[Lord Vallance of Balham (Lab)]

I reassure the noble Lord that the metro mayor was aware of the discussions with AstraZeneca. It is important to remember that AstraZeneca will continue to produce vaccines in Speke. It is not that AstraZeneca has pulled out of there; it is that the new investment has not come there. I have recently been speaking to metro mayors about how we can make sure that the R&D funding is supportive of what metro mayors are trying to achieve.